Scholarlink

<p>The prevention of chronic disease is a long-term combat with continual fine-tuning to adapt to the course of disease. Without comprehensive insights, prescriptions may prioritize short-term gains but deviate from trajectories toward long-term survival. Here we introduce Duramax, an evidence-based framework empowered by reinforcement learning to optimize long-term preventive strategies. Duramax learned from real-world treatment trajectories involving over 200 lipid-modifying drugs across more than 3.6 million months, becoming specialized in cardiovascular disease (CVD) prevention. Duramax demonstrated a superior performance in model validation using an independent cohort encompassing over 29.7 million treatment months. Specifically, Duramax achieved policy value of 93, outperforming clinicians with value of 68. When clinicians’ decisions aligned with Duramax’s suggestions, CVD risk reduced by 6%. Moreover, post hoc analysis confirmed that Duramax’s decisions were transparent and reasonable. Our research showcases how tailored computational analysis on well-curated health records can achieve high nuance in personalized disease prevention.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Optimizing long term disease prevention with reinforcement learning: a framework for precision lipid control

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年8月27日

查看全文
  • Yekai Zhou,
  • Ruibang Luo,
  • Joseph Edgar Blais,
  • Kathryn C. B. Tan,
  • David Tak Wai Lui,
  • Kai Hang Yiu,
  • Francisco Tsz Tsun Lai,
  • Eric Yuk Fai Wan,
  • Ching-Lung Cheung,
  • Ian CK Wong,
  • Celine SL Chui

摘要

The prevention of chronic disease is a long-term combat with continual fine-tuning to adapt to the course of disease. Without comprehensive insights, prescriptions may prioritize short-term gains but deviate from trajectories toward long-term survival. Here we introduce Duramax, an evidence-based framework empowered by reinforcement learning to optimize long-term preventive strategies. Duramax learned from real-world treatment trajectories involving over 200 lipid-modifying drugs across more than 3.6 million months, becoming specialized in cardiovascular disease (CVD) prevention. Duramax demonstrated a superior performance in model validation using an independent cohort encompassing over 29.7 million treatment months. Specifically, Duramax achieved policy value of 93, outperforming clinicians with value of 68. When clinicians’ decisions aligned with Duramax’s suggestions, CVD risk reduced by 6%. Moreover, post hoc analysis confirmed that Duramax’s decisions were transparent and reasonable. Our research showcases how tailored computational analysis on well-curated health records can achieve high nuance in personalized disease prevention.